Literature DB >> 16792672

Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

S Ajdary1, F Riazi-Rad, R Jafari-Shakib, M Mohebbali.   

Abstract

Leishmania infantum is the causative agent of zoonotic visceral leishmaniasis (VL). If untreated the disease could be fatal; however, in some cases the infection can run a subclinical course. In subclinical infections a Th1-response predominates, while Th2-responses and/or probably Treg cells are related to unfavourable outcome of the disease in active VL. In the present study we determined the levels of soluble (s) CD26 and CD30 co-stimulatory molecules in sera from patients with active VL, asymptomatic individuals and healthy volunteers. Results showed a significant difference in both sCD26 and sCD30 between infected cases and normal individuals (P < or = 0.001). However, there was no significant difference in sCD26 levels between asymptomatic cases and patients, although the difference was not significant. sCD30 levels were significantly higher in VL patients than asymptomatic cases (P < or = 0.001). These findings suggest a possible association between sCD26 and sCD30 levels and the clinical manifestation of L. infantum infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792672      PMCID: PMC1941995          DOI: 10.1111/j.1365-2249.2006.03105.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Cell surface characterization of T lymphocytes and allergen-specific T cell clones: correlation of CD26 expression with T(H1) subsets.

Authors:  M Willheim; C Ebner; K Baier; W Kern; K Schrattbauer; R Thien; D Kraft; H Breiteneder; W Reinisch; O Scheiner
Journal:  J Allergy Clin Immunol       Date:  1997-09       Impact factor: 10.793

2.  T-helper 2 involvement in the pathogenesis of bullous pemphigoid: role of soluble CD30 (sCD30).

Authors:  O De Pitá; A Frezzolini; G Cianchini; M Ruffelli; P Teofoli; P Puddu
Journal:  Arch Dermatol Res       Date:  1997-11       Impact factor: 3.017

3.  In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis.

Authors:  E Cillari; G Vitale; F Arcoleo; P D'Agostino; C Mocciaro; G Gambino; R Malta; G Stassi; C Giordano; S Milano
Journal:  Cytokine       Date:  1995-10       Impact factor: 3.861

4.  High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis.

Authors:  S Gasim; A M Elhassan; E A Khalil; A Ismail; A M Kadaru; A Kharazmi; T G Theander
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  Splenic cytokine responses in Indian kala-azar before and after treatment.

Authors:  R T Kenney; D L Sacks; A A Gam; H W Murray; S Sundar
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

6.  CD26 expression in leprosy and other granulomatous diseases correlates with the production of interferon-gamma.

Authors:  D Scheel-Toellner; E Richter; K M Toellner; N Reiling; H H Wacker; H D Flad; J Gerdes
Journal:  Lab Invest       Date:  1995-11       Impact factor: 5.662

Review 7.  Th1 and Th2 in human diseases.

Authors:  S Romagnani
Journal:  Clin Immunol Immunopathol       Date:  1996-09

8.  Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis.

Authors:  E M Carvalho; O Bacellar; C Brownell; T Regis; R L Coffman; S G Reed
Journal:  J Immunol       Date:  1994-06-15       Impact factor: 5.422

9.  Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi.

Authors:  E M Carvalho; A Barral; D Pedral-Sampaio; M Barral-Netto; R Badaró; H Rocha; W D Johnson
Journal:  J Infect Dis       Date:  1992-03       Impact factor: 5.226

10.  Serum levels of soluble CD30 in chronic hepatitis B virus infection.

Authors:  G Fattovich; F Vinante; G Giustina; L Morosato; A Alberti; A Ruol; G Pizzolo
Journal:  Clin Exp Immunol       Date:  1996-01       Impact factor: 4.330

View more
  7 in total

Review 1.  Systematic review of biomarkers to monitor therapeutic response in leishmaniasis.

Authors:  Anke E Kip; Manica Balasegaram; Jos H Beijnen; Jan H M Schellens; Peter J de Vries; Thomas P C Dorlo
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

2.  Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing.

Authors:  Igor Pavlov; Thomas B Martins; Julio C Delgado
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

3.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

Review 4.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

5.  Risk of classical Kaposi sarcoma by plasma levels of Epstein-Barr virus antibodies, sCD26, sCD23 and sCD30.

Authors:  Colleen Pelser; Jaap Middeldorp; Sam M Mbulaiteye; Carmela Lauria; Angelo Messina; Enza Viviano; Nino Romano; Francesco Vitale; James J Goedert
Journal:  Infect Agent Cancer       Date:  2010-10-12       Impact factor: 2.965

6.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

Review 7.  A screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?

Authors:  Johan van Griensven; Ermias Diro; Rogelio Lopez-Velez; Koert Ritmeijer; Marleen Boelaert; Ed E Zijlstra; Asrat Hailu; Lutgarde Lynen
Journal:  PLoS Negl Trop Dis       Date:  2014-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.